Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients
Autore:
Iso, K; Tada, H; Kuboki, K; Inokuchi, T;
Indirizzi:
Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, Tokyo 1438541, Japan TohoUniv Tokyo Japan 1438541 ternal Med 2, Ota Ku, Tokyo 1438541, Japan Shironishi Hosp, Shironishi Med Fdn, Dept Internal Med, Nagano 3908648, Japan Shironishi Hosp Nagano Japan 3908648 Internal Med, Nagano 3908648, Japan
Titolo Testata:
JOURNAL OF DIABETES AND ITS COMPLICATIONS
fascicolo: 5, volume: 15, anno: 2001,
pagine: 241 - 244
SICI:
1056-8727(200109/10)15:5<241:LEOEAA>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
POLYOL-PATHWAY; MESANGIAL CELLS; HIGH GLUCOSE; RATS; SORBINIL; ACCUMULATION; TOLRESTAT;
Keywords:
aldose reductase inhibitor; urinary albumin excretion; renal function; diabetic nephropathy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Iso, K Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, 6-11-1 Omori Nishi, Tokyo1438541, Japan Toho Univ 6-11-1 Omori Nishi Tokyo Japan 1438541 kyo1438541, Japan
Citazione:
K. Iso et al., "Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients", J DIABET C, 15(5), 2001, pp. 241-244

Abstract

The aim of the present study was to elucidate the long-term effect of epalrestat, an aldose reductase inhibitor (ARI), on renal function in patients with type 2 diabetes mellitus showing microalbuminuria. Patients were allocated to two groups (cases and controls) matched for age, BMI, and the extent of urinary albumin excretion (UAE). Thirty-five type 2 diabetic patients presenting microalbuminuria were included in this study: cases were treatedwith epalrestat (150 mg/day) for 5 years. No significant changes were found in blood pressure, HbA1c, and total cholesterol in either group during the observation period. In the control group, UAE increased significantly (P<.01) from 82<plus/minus>12 mg/g Cr at the baseline to 301 +/- 111 mg/g Cr at the end of the study, while UAE remained unchanged, 81 +/- 15 mg/g Cr at the baseline and 87 +/- 19 mg/g Cr at the end of the study, in the epalrestat-treated group. Reciprocal creatinine measured by an enzyme assay decreased significantly (P<.01) in both groups; however, the reduction rate in theepalrestat-treated group was significantly (P<.05) smaller than that in the control group. These results suggest the potential usefulness of ARIs in preventing the progression of incipient diabetic nephropathy in patients with type 2 diabetes mellitus. (C) 2001 Elsevier Science Inc. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 09:52:33